Application of Targeted Next-generation Sequencing, TruSeq Custom Amplicon Assay  for Molecular Pathology Diagnostics on Formalin-fixed and Paraffin-embedded Samples. by Csernák, Erzsébet et al.
Erzsébet Csernák 1, János Molnár 2, Gábor E. Tusnády 2, Erika Tóth 1 
1 
 
 Manuscript title: Application of targeted-Next-Generation Sequencing, TruSeq Custom 
Amplicon assay for molecular pathology diagnostics on formalin-fixed and paraffin 
embedded samples. 
Running title: Targeted- Next-Generation sequencing for diagnostic use 
 
Authors: Erzsébet Csernák 1, János Molnár 2, Gábor E. Tusnády 2, Erika Tóth 1 
 
 
 
1 National Institute of Oncology, Department of Surgical and Molecular Pathology, H-1122 
Budapest, Hungary 
2"Momentum" Membrane Protein Bioinformatics Research Group, Institute of Enzymology, 
Research Centre for Natural Sciences, Hungarian Academy of Sciences, H-1117 Budapest, 
Hungary 
 
Correspondence: Erika Tóth, e-mail: erika66toth@gmail.com 
 
 
 
 
 
 
 
 
 
  
Erzsébet Csernák 1, János Molnár 2, Gábor E. Tusnády 2, Erika Tóth 1 
2 
 
Abstract 
The implementation of targeted therapies revolutionized oncology. As the number of new 
oncogenic driver mutations, which provide molecular targets for prediction of effective and 
selective therapies, is increasing, the implementation of fast and reliable methods by 
molecular pathology labs is very important. Here we report our results with TruSeq Custom 
Amplicon (TSCA) assay performed on formalin-fixed and paraffin embedded (FFPE) 
material. The oligo capture probes targeted the hotspot regions of ten well known oncogenes 
linked to clinical diagnosis and treatment of lung and colorectal adenocarcinomas, melanomas 
and gastrointestinal stromal tumors. Fifteen previously genotyped FFPE DNA samples from 
different tumor types were selected for massively parallel sequencing. A bioinformatics 
pipeline was developed to identify high quality variants and remove sequence artifacts. With 
the exception of one sample, which was of lower quality than the others, relevant mutations 
corresponding to tumor types could be reliable detected by the developed bioinformatical 
pipeline. This study indicates that the application of TSCA assay is a promising tool in 
molecular pathology diagnostics, but it is important to standardize sample processing 
(including fixation, isolation procedure, sample selection based on quality assessment and 
rigorous variant calling) in order to achieve the highest success rate and avoid false results. 
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Introduction 
NGS has a fundamental importance in the genetic profiling of various diseases and in the 
translation of the obtained data back into medical applications. In the field of oncology, 
molecular characterization of tumors is growing rapidly and the number of new biomarkers 
implicated in tumor progression and therapeutic sensitivity is expanding.  
As the number of new oncogenic driver lesions, which provide molecular targets for 
prediction of effective and selective therapies is increasing, the implementation of fast and 
reliable methods by molecular pathology departments is very important. The aim of molecular 
pathology labs is giving the most accurate and precise results within the shortest period of 
time. „Turnaround time“(TAT) in molecular pathology is as much important as in surgical 
pathology.  
This raises the need for deployment of high performance and rapid molecular tests that can 
screen a large panel of genes for tumor actionable mutations both specifically and accurately. 
In this respect, standard PCR based approaches can only detect a limited number of genomic 
alterations owing to low-level multiplicity. The genetic analysis should also be appropriate for 
working with DNA extracted from formalin fixed tissues, because this is the type of material 
that is generally available at routine pathological laboratories. Although numerous studies 
have been successfully used FFPE material for NGS, several caveats and considerations 
should be taken into account when we use FFPE samples for diagnostic purposes.1–3 The main 
issue with FFPE samples is DNA degradation caused by formalin fixation resulting 
incorporation of incorrect bases during PCR.4 Since artificial mutations are present at low 
rate, there could be difficulties when we use sensitive techniques to detect low frequency 
variants or to improve analysis from tissue samples with very low tumor content on a normal 
background. As NGS method implements clonal sequencing and enables low detection limit, 
the probability of erroneously identifying mutations is higher in such cases, resulting in 
reduced specificity. Nevertheless, the use of efficient bioinformatics tools has been thought to 
overcome such problems.5  
In light of this, our aim was to investigate what conditions are necessary to achieve reliable 
mutation detection from FFPE material by targeted next generation sequencing. To do this, 
formalin-fixed tumor tissues with different tumor ratio, mutational status and varying degrees 
of quality were selected. The sequencing reaction was performed on Illumina MiSeq 
instrument using TruSeq Custom Amplicon (TSCA) technology. For data evaluation we 
developed our own bioinformatics pipeline to adapt to damaged samples with particular 
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attention to removal of sequencing artifacts. Finally, we also assessed FFPE sample criteria 
concerning quality and tumor cell content required to obtain a successful sequencing result. 
 
Materials and methods 
Sample and testing selection 
We used TruSeq Custom Amplicon assay with the Illumina Miseq instrument. We expanded 
our currently used gene panels with new marker genes using Illumina DesignStudio which 
contains 3,493 Kb of cumulative sequence and 36 amplicons (Supplemental Table).   
The oligo probes targeted the hotspot regions of clinically relevant oncogenes including 
KRAS, NRAS, BRAF, EGFR, KIT, PDGFRA, MAP2K1, AKT1, PIK3CA, and FGFR2 
(Supplemental Table). Fifteen FFPE tissue samples of colorectal cancer (CRC), melanoma, 
gastrointestinal stromal tumor (GIST), and non-small cell lung cancer (NSCLC) patients were 
selected for targeted-NGS, harboring known mutations in oncogenes previously detected by 
in-house fluorescence probe based real-time PCR assay, Sanger sequencing and Cobas KRAS 
and EGFR mutation tests (Roche Diagnostics). 
 
Sample preparation and DNA quality assessment 
Prior to isolation, the tumor / normal cell ratio was estimated by our local pathologist on 
hematoxylin and eosin (H&E) stained slides and tumor tissues were macro dissected from a 
single representative block. Depending on the diameter of the tumor area, three or five 5µm 
sections were deparaffinized and subjected to cell lysis with proteinase K treatment at 56 ºC 
for 24 hours. After this, DNA extraction was carried out with the Cobas DNA Sample 
Preparation kit (Roche Diagnostics) according to the manufacturer’s instruction. The purified 
DNA concentration was determined by fluorescent method using the Quant-iT High-
Sensitivity DNA Assay Kit (Life Technologies). We used two PCR based quality control 
methods namely the Illumina FFPE QC assay (Illumina) and KAPA hgDNA Quantification 
and QC Kits (Kapa Biosystems) in order to assess whether there is sufficient number of 
amplifiable template in the DNA sample for library construction. 
 
Library preparation and sequencing analysis 
Library preparation was performed according to the TSCA protocol. The successfully 
produced samples were pooled and sequenced on the Illumina MiSeq instrument using the 
Miseq reagent nano kit v2 generating 2x150 paired-end reads at a level of 300Mb output. The 
reads were aligned to the human (Homo sapiens) reference sequence version GRCh37.7, 
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which was obtained from the Ensembl database.6 The alignments of paired-end reads were 
generated with the bwa-mem algorithm. Duplicated reads were removed from the alignment 
by the Picard tool MarkDuplicates. The SAMtools7 pipeline was used in the variant-calling 
process.  
 
Filtering out sequencing artefacts 
Generating the final variants from the deduplicated alignments, we used strict filtering 
options. In case of single nucleotide variants, the variant must be covered with high quality 
reads from each sequencing strand at least one time and the Phred variant quality must be 
equal or higher than 45. Additionally, when the number of high quality reads is less than 5 the 
alternative variant containing high quality reads must be equal or greater than 2, else the ratio 
of alternative variant containing reads must be greater than 0.25. In  case of short indels, the 
variants must be covered with high quality reads containing the variant from each sequencing 
strand at least one time and the Phred variant quality must be equal or higher than 45. 
Additionally, if the coverage of high quality reads is 4 than the alternative variant must be 
covered with high quality reads at least two times. Else the ratio of alternative variant 
containing reads must be greater than 0.25. These criteria were used to distinguish sequencing 
artefacts (e.g. formalin induced mutations) from real heterozygous variants. Finally the 
detected variants were annotated by the Ensembl Variant Effect Predictor8. 
 
Results 
Library construction from FFPE samples 
Table 1  shows the results of DNA quality assessment. We determined those parameters that 
mainly affect the success of library preparation. The DNA concentration had minimal 
influence, because as little as 5 ng/µl worked properly (case 5, Table 1) which is favorably 
lower than 25 ng/µl specified in the protocol. This flexibility is likely because of the fact that 
the FFPE samples contain certain amount of single stranded DNA, which is also suitable for 
amplicon based assays unlike other types of library preparation protocols, where double 
stranded DNA is required. However, it should be noted that if the concentration was too low 
as in case 3 (0.4ng/µl), the sample didn’t function for TSCA even if it was of good quality 
(Table 1).  
We used two quantitative real-time PCR (qPCR) assays to assess the amplification efficiency 
of the input DNA. The Illumina FFPE QC Kit calculates a ∆Ct value, which is a subtraction 
of the quantification threshold cycle (Ct) of a control template included in the kit, from the Ct 
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value of a given sample, both used in equal concentration. According to the 
recommendations, all samples with values below or equal to 2 can be selected for TSCA. 
Interestingly, case 1 with 1.7 ∆Ct didn’t work; by contrast, case 14 with 2.4 ∆Ct gave good 
result (Table 1). These minimal discrepancies can be attributed to the fact that the ∆Ct value 
only characterizes the amplification capacity of a defined target length and does not give any 
information if there is sufficient number of amplifiable template in wider size range, that is 
the extent of fragmentation in damaged FFPE DNA. Using KAPA hgDNA Quantification and 
QC assay allows us to get this kind of quality information by measuring Q129/Q41 ratio. For 
calculating this value, standard curves were generated with amplifying targets of 41bp and 
129bp in the human genome. The relative quality can be derived by normalizing the 
concentration obtained with the 129bp assay against the concentration from the 41bp assay. 
The value can vary between 0 and 1, depending on the sample quality. We found that a 
Q129/Q41 ratio below 0.2 was a negative predictor of library success. These values could also 
explain the deviations mentioned above at cases 1 and 14, by modifying the expected 
outcome based on ∆Ct. For sample 4, despite its poor quality (Q=0,104) the library worked 
well probably due to its good amplification efficiency (Table 2). In spite of the low quality, 
we carried out the subsequent sequencing analysis to see its influence on final data 
interpretation. Based on the 129bp assay, we also calculated a ∆Ct value (by subtracting the 
expected Ct value of a sample calculated from its concentration and standard curve, from the 
measured Ct) that gave relatively small differences to Illumina QC ∆Ct, which was likely 
caused by the various lengths of targets used in qPCRs. The inconsistency of samples 1 and 
14 was also observed at the Q129 ∆Ct value, which confirmed the necessity of using the 
Q129/Q41 ratio or a similar quality value for better selection of samples suitable for 
sequencing (Table 1). 
 
TSCA assay results 
Sequencing metrics  
Full coverage was relatively high (6929 in average, range between 4764-8342) due to limited 
samples were running, but this could be corrected, and it did not affect the recovery of data. 
The TSCA sequencing run gave an excellent specificity, (defined as the percent of filtered 
reads mapping to target regions) and was very similar among formalin-fixed samples at an 
average value of 96.6%. We assessed the uniformity of target read distribution between 
amplicons and samples after duplicate removal (Figure 1). The coverage values deviated from 
what we expected, with a range from 8.45 +/- 3.77 to 21.34 +/- 7.94 within the samples, 
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which may reflect the uneven quality of FFPE samples available for sequencing. Furthermore, 
this variation can be seen within the amplified regions as well (Figure 1). It should be noted 
that due to the deduplication of redundant sequences (PCR duplicates) our relative coverage 
seems quite small (Figure 1), but this step was important to improve variant calling and 
eliminate bias influencing the real allelic representation of the sample. In the cases of 
NRASex3, AKT1ex2, and EGFRex20 target regions, a high GC sequence content (above 
80%) was found near the TSCA oligo probes that likely caused this observation. However, 
these discrepancies did not affect the reference mapping and the subsequent variant calling. 
 
Detecting high quality variants 
Using our variant detection pipeline, we were able to identify high quality variants (Table 2). 
As our experience showed, it is crucial to remove the duplicated sequences, which can 
interfere the variant calling by the biased read coverage (Figure 2). This was presented in 
other publication as well, i.e. the FFPE samples contain high number of PCR duplicates 
within the 60% - 85% range9. We made a test about the reliability of variant calling. The 
selected loci (KIT_ex11) from sample 11 was downsampled using the Picard 
tool DownsampleSam within the range of 100%-10% (the coverage was in the range from 16 
to 2), and we were able to identify the alternative allele when the covarege was as low as two. 
Using this knowledge, we achieved a high concordance in the identification of clinically 
relevant mutations that were previously characterized by our currently used laboratory tests. 
In case of sample 4 we were not able to apply our strict automated variant detection pipeline 
to identify mutations, as it generated a proportionately high number of low-quality reads 
making it unsuitable for reliable analysis.  
 
Discussion 
The advents of next generation sequencing technologies have opened the possibility to get 
enormous amount of genetic information from a given sample and have a deeper knowledge 
of the association between the genomic structure and function, and various biological 
processes or diseases. Applying this information in clinical practice has many benefits 
including refining diagnosis, individualizing treatments, predicting drug effects or developing 
new therapies.10 In light of these advantages, we considered the possibilities to replace our 
currently used low scale diagnostic tests with a large scale NGS method. Using fifteen pre-
selected FFPE tumor tissue samples as controls harboring clinically important mutations, we 
investigated the main criteria required to the successful adoption of NGS in clinical 
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diagnostics. Basically, two target enrichment techniques can be applicable for this purpose: 
amplicon-based and sequence capture approaches. We chose an amplicon based method, 
because we focused on a small set of clinically important genes with defined hotspots. We 
preferred TruSeq custom amplicon (TSCA) assay as it has simple workflow, the entire 
procedure takes only two days, thus allowing short turnaround time of reports and rapid and 
efficient patient management. In addition, during work with million copies of PCR amplicons, 
care must be taken to avoid cross-contamination between templates. In this regard, TSCA 
seemed to us more optimal than other amplicon based sequencing strategies, because only a 
reduced cycling time PCR occurs when sample-specific indices are added to each library, 
thereby minimizing the possible presence of unwanted constituents.  
We tested DNA samples obtained from formalin-fixed, paraffin-embedded tissue blocks. 
Although this type of material has great potential in clinical medicine, due to the fixation 
process DNA can be degraded at various degrees, which can impact the reliability and quality 
of genetic analyses. For NGS, high quality starting material is essential for reliable and 
accurate sequencing results, therefore qualitative monitoring of FFPE DNA specimens is an 
important step. Using different qPCR methods we assessed the main parameters that best 
characterize the quality of the samples and predict the success of assay performance. The 
samples used in our experiments were obtained from a variety of tissue types and hospitals 
using different fixation and embedding protocols. As it was expected, the level of degradation 
and quality between samples varied over a wide range (Q: 0.052-0.91, Table 2). The best 
approach to determine the quality of DNA is proved to be a qPCR assay targeting different 
sizes of genomic regions. This method gives the most precise information about DNA 
degradation level. Our results show that at the moment the quality requirements are higher for 
NGS compared to conventional PCR techniques (sequencing was successful in 67% of our 
FFPE samples), but it can be improved in the future by using more standardized protocols for 
tissue fixation, and DNA isolation tailoring to the particularities of FFPE material.  
For accurate variant detection it is essential to reach consistent uniformity and minimum 
required depth of coverage of target regions. The amplicon-based technique has the advantage 
of generating more uniform coverage across all target bases than sequence capture approach, 
however it is possible that the poor amplification of some targets mainly caused by high GC 
content as presented above. Low or no coverage regions could produce false negative results, 
which is not acceptable in diagnostic applications. In our case, 8% of the target amplicons 
were underrepresented. With our high coverage depth, we achieved a few hundred fold 
coverage in these regions, which proved to be sufficient for accurate variant calling. In the 
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future more emphasis should be placed on optimal probe design to obtain more consistent 
coverage and avoid false results. On the basis of our findings, for accurate variant calling 
needs at least one high quality read from both the reverse and forward strand after duplicate 
removal. But the minimal required raw read number/coverage is hard to tell: this depends 
highly on sample quality, and more data will be needed to predict precisely 
In case of FFPE samples, it should  be taken into account that the samples do not amplify in 
the same quality, resulting in  greater variability in the distribution of sequencing reads and 
piling up high number of PCR duplicates within the 60% - 85% range. Developing an 
alternative PCR amplification protocol could solve this problem.11 
A properly configured bioinformatics pipeline is essential for high confidence variant 
detection. Aligned to the properties of FFPE samples, we introduced rigorous filtering 
parameters including duplicate removal, minimal coverage of high quality reads representing 
the alternate allele, coverage from the forward and reverse sequencing strand, and higher 
variant quality as well. Using our strict filtering pipeline, we were able to detect short genetic 
variants and filter out sequencing errors and artifacts caused by the formalin fixation. We 
identified safely the previously detected genetic variants of samples with tumor cell content 
between 40-90%. Due to the very useful nature of sequencing, we were able to detect other 
genetic variants in the selected regions as well, which enables even finer determination of the 
different mutations.  
It is also important to consider when applying diagnostics tests that the quality of the samples 
determines data quality; bioinformatics could not manage every input data optimally, as it was 
seen in the case of our samples. Therefore it is essential to set up quality criteria for efficient 
sequencing. 
In summary, we described the feasibility of successful validation of targeted NGS for 
molecular pathology diagnosis of different hot spot mutations in FFPE samples. As the 
number of targetable genes increasing in oncology, it becomes more important to implement 
NGS workflows into the routine laboratory work. 
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Titles and legends to figures 
 
 
Figure 1 Coverage distribution among the eleven samples after duplicate removal 
Median coverage values were calculated for every amplified region within one sample. For 
every amplified region the average value was determined from these coverage data among the 
samples, and the standard deviation was calculated as well. The blue bars represent the 
average values for the amplified region, and the standard deviation values are visualized as 
well 
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Figure 2 Example of sequence results 
Manual inspection by the IGV program (Robinson et al. 2011) of the NGS reads (a) and the 
sequencing chromatograms from Sanger method (b) shows the same genotypes. In the case of 
NRAS the Sanger sequencing data is from the sense strand, which is reversed to the human 
genomic reference sequence 
 
 
 
 
 
